Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 19/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19307731 | 0.91 | SLC22A2 (0.66) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL20007791 | 0.89 | SLC22A2 (0.67) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL29775439 | 0.86 | SLC22A2 (0.69) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL22584730 | 0.86 | SLC22A2 (0.69) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL80723 | 0.86 | SLC22A2 (0.69) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL29775471 | 0.86 | SLC22A2 (0.69) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL82516 | 0.86 | SLC22A2 (0.69) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19177949 | 0.85 | SLC22A2 (0.68) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL18461832 | 0.85 | SLC22A2 (0.68) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19327604 | 0.84 | SLC22A2 (0.74) | SLC22A2CYP3A4TMEM97ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778943-B2 | Substituted 10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1h-pyrido[1,2-α]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazine-8-carboxamides | SHIONOGI & CO., LTD. (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20130172559-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE COMPANY (US) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172559-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | SLC22A2 2976/4885CYP3A4 28/4885TMEM97 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.